News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Revolutionary new Centre for Cancer Drug Discovery aims to deliver step change in cancer treatment
The world’s first ‘Darwinian’ drug discovery programme specially designed to tackle cancer’s lethal ability to evolve resistance to treatment is to be launched in a state-of-the-art new building in London.
New radiotherapy system that moves patients in sync with x-ray beam can deliver accurate treatment for brain cancer
A new way to deliver radiotherapy that rotates patients in sync with the treatment beam could treat patients with brain cancer as accurately and quickly as the most advanced radiotherapy available, scientists at the ICR show.
New treatment could become first ever targeted therapy designed for ‘untreatable’ childhood brain cancer
A new type of drug that targets a genetic weakness in an untreatable childhood brain cancer could become the first ever treatment designed to target the disease. The prototype treatment could also offer hope for patients with the rare and devastating ‘stone man syndrome’ – in which muscles and ligaments turn to bone.
Gene mutation discovery linked to very poor survival in prostate cancer patients
Scientists have identified a gene mutation in the tumours of men with prostate cancer that is linked to very poor survival – and which could be used to pick out patients for more intensive treatment.
ICR is most successful UK university for invention income for sixth consecutive year
The Institute of Cancer Research, London has once again earned the most invention income per member of research staff of any UK higher education institution for the past academic year.
Two-for-one molecule could target two key drivers of aggressive childhood cancer
A group of molecules which each simultaneously target two of the most common genetic faults behind an aggressive form of childhood cancer could lead to a potential new drug for the disease, a new ICR study suggests.
New panel of genes identifies men at highest risk of aggressive prostate cancer
A new panel of genes could pick out men at highest risk of developing prostate cancer and pick out those already diagnosed who are likely to have particularly aggressive forms of the disease, a large-scale genetic analysis has found.
Manifesto calls for action on cancer drug access as survey shows patient delays
Our new 10-point manifesto is calling for action to speed up access to innovative cancer drugs as an accompanying survey of 1,000 cancer patients finds many face barriers in receiving the latest treatments.
Targeted breast cancer drug – olaparib – given green light by EU
European Medicines Agency approves olaparib for women with BRCA-mutant breast cancer – 15 months after licensing in the US.
Cancers ‘change spots’ to avoid immunotherapy
Cancers can make themselves harder for new immunotherapies to see by ‘changing their spots’ – and switching off a key molecule on the surface of cells that is otherwise recognised by treatment.
Three-pronged attack can overcome drug resistance in bowel cancer
Researchers at the ICR show that triple drug combinations could prevent resistance in many cancer types.
Sutton MP – Paul Scully – becomes cancer researcher for the day at the ICR
Local MP Paul Scully donned a lab coat and safety specs to spend a day as a cancer researcher working in the Sutton laboratories of the ICR.
